On August 25, 2023, Decibel Therapeutics, Inc. announced that the U.S. Food and Drug Administration had granted fast track designation for DB-OTO, the Company?s lead gene therapy product candidate for congenital hearing loss caused by mutations of the otoferlin gene.
Decibel Therapeutics, Inc.
Equities
DBTX
US24343R1068
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+49.56% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |